Susquehanna Fundamental Investments LLC Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 228,513 shares of the company's stock, valued at approximately $9,995,000. Susquehanna Fundamental Investments LLC owned 0.14% of Revolution Medicines as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new stake in Revolution Medicines in the 4th quarter worth approximately $34,000. Sterling Capital Management LLC increased its position in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after buying an additional 1,672 shares during the period. Farther Finance Advisors LLC lifted its holdings in Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after buying an additional 1,613 shares during the period. Daiwa Securities Group Inc. boosted its position in Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock valued at $165,000 after acquiring an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in shares of Revolution Medicines in the 4th quarter worth approximately $173,000. 94.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RVMD has been the subject of several recent research reports. UBS Group raised their price objective on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Stifel Nicolaus dropped their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. HC Wainwright increased their target price on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Wedbush restated an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research note on Monday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $59.00 target price on shares of Revolution Medicines in a research report on Tuesday, April 8th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines has a consensus rating of "Buy" and a consensus target price of $66.67.

Insider Buying and Selling

In other news, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Jack Anders sold 1,864 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is owned by corporate insiders.

Revolution Medicines Trading Up 0.6 %

NASDAQ RVMD traded up $0.26 on Thursday, reaching $40.64. 1,555,467 shares of the stock were exchanged, compared to its average volume of 1,448,703. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The firm has a market capitalization of $7.56 billion, a PE ratio of -11.32 and a beta of 1.37. The company's 50-day simple moving average is $37.36 and its two-hundred day simple moving average is $43.90.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Sell-side analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.